Does Entyvio Cause GERD?
No, there is no evidence that Entyvio (vedolizumab) causes gastroesophageal reflux disease (GERD). The provided evidence does not contain any information linking Entyvio to GERD as a side effect or complication.
Important Clarification
Entyvio is vedolizumab, not natalizumab - The expanded question incorrectly identifies Entyvio as natalizumab, but these are two distinct medications. Entyvio (vedolizumab) is a gut-selective integrin antagonist used for inflammatory bowel disease (ulcerative colitis and Crohn's disease). 1, 2, 3, 4
No drug label or guideline evidence provided - The evidence supplied focuses entirely on GERD diagnosis, management, and extraesophageal manifestations, but contains no information about Entyvio/vedolizumab or its potential to cause or exacerbate GERD. 5
GERD Context from Evidence
The provided guidelines extensively discuss:
GERD is multifactorial with mechanisms including anti-reflux barrier dysfunction, impaired esophageal clearance, gastric motility issues, and mucosal integrity problems. 4
Common GERD triggers include medications such as alendronate, oral corticosteroids, bronchodilators, calcium channel blockers, and anticholinergic agents - but biologics like Entyvio are not mentioned. 5
Diagnosis requires either typical symptoms (heartburn, regurgitation) responding to PPI therapy, or objective testing with endoscopy and prolonged pH monitoring. 5
Clinical Recommendation
If a patient on Entyvio develops GERD symptoms, evaluate and manage the GERD according to standard protocols rather than attributing it to the medication. Begin with a 4-8 week trial of single-dose PPI therapy taken 30-60 minutes before meals, and reassess response. 5 Consider other contributing factors such as obesity, dietary habits, hiatal hernia, or concomitant medications known to worsen reflux. 5